To our knowledge, there is no prospective trial comparing monotherapy and combination therapy in NSCLC with high PD-L1 expression, which would be of interest to further investigate if a better survival for combination therapy applies to all relevant subgroups, and if there are patient characteristics that may further guide choice of therapy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.